

To achieve value driven leadership in Indian Health Care Industry and beyond... Through Quality that is infinite Service that cares Hardwork that endures

22nd March, 2019

| The Corporate Relationship Department | National Stock Exchange of India Limited |
|---------------------------------------|--|
| BSE Limited | Exchange Plaza, |
| Phiroze Jeejeebhoy Towers, | Bandra Kurla Complex, |
| Dalal Street, | Bandra East, |
| Mumbai 400 001. | Mumbai 400 051. |
| Scrip Code: 539523 | Scrip Symbol: ALKEM |

Dear Sirs,

Sub: Update on US FDA Inspection at Alkem's manufacturing facility located at St. Louis, USA

In furtherance to the intimation captioned "US FDA Inspection at Alkem's manufacturing facility located at St. Louis, USA" dated 6th February, 2019, this is to inform you that the Company had submitted a detailed response to the eight (8) Form 483 observations that it had received during a pre-approval inspection for a product at the Company's manufacturing facility located at St. Louis, USA.

The Company has now received a letter from the US FDA informing that the manufacturing of the said product be withheld until the completion of the final evaluation by the USFDA and the final decision of the US FDA shall be communicated to the Company accordingly. It is to be noted that the said product is not being manufactured at this time as it is awaiting approval from US FDA.

Kindly take the same on record.

Sincerely, For Alkem Laboratories Limited

LON a

Manish Narang President - Legal, Company Secretary & Compliance Officer